Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: Perspectives on intranasal administration

Journal of Urban Health

Volumn 85, Issue 3, 2008, Pages 352-360

  Kerr, Debra ^a   Dietze, Paul ^c,d   Kelly, Anne Maree ^a,b   Jolley, Damien ^d  

^a SUNSHINE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BURNET INSTITUTE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Heroin; Intranasal; Naloxone; Overdose

Indexed keywords

DIAMORPHINE; NALOXONE;

ADULT; ARTICLE; ATTITUDE; AUSTRALIA; CONTROLLED STUDY; DEMOGRAPHY; DRUG OVERDOSE; EMERGENCY TREATMENT; FEMALE; HEROIN DEPENDENCE; HUMAN; LEGAL ASPECT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SAMPLING; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ATTITUDE TO HEALTH; AUSTRALIA; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OVERDOSE; PEER GROUP; QUESTIONNAIRES; SUBSTANCE ABUSE, INTRAVENOUS; URBAN HEALTH SERVICES;

EID: 42549120780     PISSN: 10993460     EISSN: 14682869     Source Type: Journal    
DOI: 10.1007/s11524-008-9273-z     Document Type: Article

References (28)

1. Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: II. Responses to overdose. Addiction. 1996;91(3):413-417.
2. Strang J, Powis B, Best D, et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction. 1999;94(2):199-204.
3. McGregor C, Darke S, Ali R, Christie P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction. 1998;93(5):701-711.
4. Darke S, Ross J, Zador D, Sunjic S. Heroin-related deaths in New South Wales, Australia, 1992-1996. Drug Alcohol Depend. 2000;60(2):141-150.
5. Davidson PJ, Ochoa KC, Hahn JA, Evans JL, Moss AR. Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco. Addiction. 2002;97(12):1511-1516.
6. Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health. 2003;80(2):291-301.
7. Tracy M, Piper TM, Ompad D, et al. Circumstances of witnessed drug overdose in New York City: implications for intervention. Drug Alcohol Depend. 2005;79(2):181-190.
8. Darke S, Hall W. The distribution of naloxone to heroin users. Addiction. 1997;92(9):1195-1199.
9. Lenton SR, Hargreaves KM. Should we conduct a trial of distributing naloxone to heroin users for peer administration to prevent fatal overdose? Med J Aust. 2000;173(5):260-263.
10. Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med. 2007;49(2):172-177.
11. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction. 2005;100(12):1823-1831.
12. Wright N, Oldham N, Francis K, Jones L. Homeless drug users' awareness and risk perception of peer "Take Home Naloxone" use-a qualitative study. Subst Abuse Treat Prev Policy. 2006;1:28.
13. Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82(2):303-311.
14. Worthington N, Markham Piper T, Galea S, Rosenthal D. Opiate users' knowledge about overdose prevention and naloxone in New York City: a focus group study. Harm Reduct. 2006;3:19.
15. Tobin KE, Gaasch WR, Clarke C, MacKenzie E, Latkin CA. Attitudes of emergency medical service providers towards naloxone distribution programs. J Urban Health. 2005;82(2):296-302.
16. Mountain D. Take home naloxone for opiate addicts Big conclusions are drawn from little evidence. BMJ. 2001;323(7318):934, author reply 5.
17. Ashworth AJ, Kidd A. Take home naloxone for opiate addicts. Apparent advantages may be balanced by hidden harms. BMJ. 2001;323(7318):935.
18. Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;322(7291):895-896.
19. Stata Statistical Software: release 8.2. College Station, Texas Stata Corporation, 2003.
20. DHS. The Victorian drug statistics handbook 2006: patterns of drug use and related harm in Victoria. Melbourne, Victoria: Drugs Policy and Services Branch, Rural and Regional Health and Aged Care Services Division; 2006.
21. Lagu T, Anderson BJ, Stein M. Overdoses among friends: drug users are willing to administer naloxone to others. J Subst Abuse Treat. 2006;30(2):129-133.
22. Kelly AM, Kerr D, Dietze P, et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182(1):24-27.
23. Robertson T, Hendey G, Stroh G, Shalit M. Intranasal versus intravenous naloxone for prehospital narcotic overdose (abstract). Acad Emerg Med. 2005;12:s166-s167.
24. Baca CT, Grant KJ. What heroin users tell us about overdose. J Addict Dis. 2007;26(4):63-68.
25. Dietze P, Fry C, Rumbold G, Gerostamoulos J. The context, management and prevention of heroin overdose in Victoria, Australia: the promise of a diverse approach. Addiction Research and Theory. 2001;9(5):437-458.
26. Cantwell K, Dietze P, Flander L. The relationship between naloxone dose and key patient variables in the treatment of non-fatal heroin overdose in the prehospital setting. Resuscitation. 2005;65(3):315-319.
27. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis. 2006;25(3):89-96.
28. Sherman SG, Gann DS, Scott G, Carlberg S, Bigg D, Heimer R. A qualitative study of overdose responses among Chicago IDUs. Harm Reduct J. 2008;5(1):2.